GLAXO
1450
2019-01-04
GLAXOSMITHKLINE PHARMACEUTICALS LTD.
Profitability metrics STANDALONE CONSOLIDATED
Asset Turnover 0.7274 0.7305
Current ratio 1.41 1.43
WC days 97.69 100.8
EBITDA (%) 20.02 19.97
FCF (Rs Cr.) 61.12 61.97
ROCE (%) 26.04 26.24
ROE (%) 16.92 17.05

Solvency metrics STANDALONE CONSOLIDATED
Cash Ratio 0.67 0.68
Div. payout (%) 84.23 850
Int. Coverage 2851.47 2842.95
LT D/E 0 0
Solvency Ratio 393.92 392.65

Valuation STANDALONE CONSOLIDATED
Beta 0.5742 0.5742
Div. yield (%) 2 17
EV (Rs Cr.) 16384.6 16367.9
P/BV 8.49 8.59
P/E 50.18 50.36
PEG 10.04 12.59
P/S 6.1 6.1

Balance sheet metrics STANDALONE CONSOLIDATED
BV/share 245.57 242.9
3Y growth BV/s (%) 12 12
Cash (Rs Cr.) 1279.69 1296.41
Total Debt (Rs Cr.) 0.99 0.99
Net block (Rs Cr.) 324.57 324.59

P&L metrics STANDALONE CONSOLIDATED
DPS 35 351.97
EPS 41.56 41.41
Net Income (Rs Cr.) 351.99 350.73
Operating profit (Rs Cr.) 508.44 505.8
No. of o/s shares 8.47 8.47
Revenue (Rs Cr.) 2895.88 2895.65
Total Income (Rs Cr.) 2967.2 2967.99

Cash Flow metrics STANDALONE CONSOLIDATED
CEPS (%) 5605 5582
3Y growth CEPS 0.39 0.4
CFF (Rs Cr.) -306.63 -306.63
CFI (Rs Cr.) -107.01 -104.19
CFO (Rs Cr.) 474.77 472.8
FCF (Rs Cr.) 61.12 61.97
3Y growth Op. CF (%) 39 40

Growth metrics STANDALONE CONSOLIDATED
3Y growth dividends (%) -44 -44
1Q growth EBITDA (%) 0 0
3Y growth EBITDA (%) -25 -26
4Q growth EBITDA (%) 0 0
1Q growth EPS (%) 0 0
3Y growth EPS (%) -25 -26
4Q growth EPS (%) 0 0
3Y growth Net inc. (%) -25 -26
1Y growth Op. CF (%) 104 100
1Q growth revenue (%) 0 0
3Y growth revenue (%) -12 -12
4Q growth revenue (%) 0 0